All In Biotech

Drug Trial Radar · NCT02484092

A Gene Therapy Study for Hemophilia B

Gene Therapy, Open-label, Dose-escalation Study of PF-06838435 (SPK-9001) [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B

Last checked: Nov 20, 2026Latest source record: Jun 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Nov 18, 2015

Primary completion

Apr 8, 2019

Study completion Apr 8, 2019

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2, Open-Label, Non-Randomized, Dose-Escalation Study of SPK-9001 in Subjects with Hemophilia B.

Conditions

  • Hemophilia B

Interventions

  • SPK-9001Biological

    A novel, bioengineered adeno-associated viral vector carrying human factor IX variant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinically Significant Change From Baseline in Physical Examination FindingsTime frame: Baseline up to Week 52
  2. Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Baseline up to Week 52
  3. Number of Participants With Clinical Laboratory Abnormalities Reported as TEAETime frame: Baseline up to Week 52
  4. Number of Participants With Drug -Related TEAEs and Serious Adverse Events (SAEs)Time frame: Baseline up to Week 52
  5. Number of Participants With Positive Immune Reponses Against Adeno-associated Virus Vector (AAV) CapsidTime frame: Baseline up to Week 52
  6. Number of Participants Who Reached > 150% Vector-derived FIX:C Activity Level After SPK-9001 InfusionTime frame: Baseline up to Week 52
  7. Number of Participants With FIX InhibitorTime frame: Baseline up to Week 52
  8. Incremental Recovery of FIX ProductTime frame: Day 0 and Week 52

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • UC Davis CTSC Clinical Research Center

    Sacramento, California

  • UC Davis Ellison Ambulatory Care Clinic

    Sacramento, California

  • UC Davis Investigational Pharmacy

    Sacramento, California

  • UC Davis Medical Center

    Sacramento, California

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi

  • Weill Cornell Medicine - New York Presbyterian Hospital

    New York, New York

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Royal Prince Alfred Hospital

    Camperdown/Sydney, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.